Camurus
535 SEK +7.82%7 investors are following this company
Camurus is active in biotechnology. The company runs as a research-based pharmaceutical company and develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders, and patients with opioid dependence. Camurus runs development projects under its own auspices and in partnership with international pharmaceutical companies. The company is headquartered in Lund.
Revenue
1.72B
EBIT %
30.63 %
P/E
68.77
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CAMX
Daily low / high price
503.5 / 541.5
SEK
Market cap
30.83B SEK
Turnover
96.7M SEK
Volume
182K
Latest videos
Financial calendar
Interim report
16.07.2024
Interim report
07.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Sandberg Development AB | 37.9 % | 37.9 % |
Fjärde AP-fonden | 4.3 % | 4.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Camurus, Audiocast with teleconference, Q1, 2024
Camurus AB: Camurus' Interim Report January-March 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools